title: NICE guidance on enzalutamide for metastatic   hormone-relapsed prostate cancer.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Elsada
authors.forename: Fiona
authors.initials: F
authors.lastname: Pearce
authors.forename: Elisabeth
authors.initials: E
authors.lastname: George
authors.forename: Amanda
authors.initials: A
authors.lastname: Adler
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001549:Benzamides; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D009313:National Health Programs; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014481:United States
chemical_list: D000726:Androgen Antagonists; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide